133 / 1416
Rationale: modern perspectives
• The « new » era : since the 2000s:
– Need to fight back in the raising competition with
IMXRT that also allows safe dose-escalation
studies
– Need to keep-up with modern « environment » of
Rtherapy: easiness, reliability (gantries, absence
fiducials), safety and reproducibility (QA, IGRT,
adaptive, in vivo dosimetry…)
– Need to be evaluated in the full context of
multimodal armamentarium…